Paper23398482
Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.
Teuffel O and 5 others. Br J Haematol, 2013. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Papers, record 23398482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23398482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Daunorubicin | Major topic |
| Idarubicin | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Adult | |
| Child | |
| Child, Preschool | |
| Disease-Free Survival | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Infant | |
| Male | |
| Middle Aged | |
| Remission Induction | |
| Survival Rate |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 87719 | Canadian Institutes of Health Research | Canada | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03023384 | Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML | Background |
Source ClinicalTrials.gov
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40427048 | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries. | Biomedicines | 2025 | https://conductscience.org/library/papers/40427048 | PubMed |
| 40136430 | The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40136430 | PubMed |
| 39555737 | Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. | Am J Hematol | 2025 | https://conductscience.org/library/papers/39555737 | PubMed |
| 39415901 | Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced? | EJHaem | 2024 | https://conductscience.org/library/papers/39415901 | PubMed |
| 38321873 | Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital. | J Oncol Pharm Pract | 2025 | https://conductscience.org/library/papers/38321873 | PubMed |
| 38290791 | Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. | Toxicol Sci | 2024 | https://conductscience.org/library/papers/38290791 | PubMed |
| 38095652 | The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/38095652 | PubMed |
| 38066853 | Improving long-term outcomes with intensive induction chemotherapy for patients with AML. | Hematology Am Soc Hematol Educ Program | 2023 | https://conductscience.org/library/papers/38066853 | PubMed |
| 37212948 | Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy. | Int J Hematol | 2023 | https://conductscience.org/library/papers/37212948 | PubMed |
| 36765533 | At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765533 | PubMed |
| 35833221 | Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase. | J Oncol Pharm Pract | 2026 | https://conductscience.org/library/papers/35833221 | PubMed |
| 35680595 | [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | https://conductscience.org/library/papers/35680595 | PubMed |
| 35526025 | The dual role of autophagy in acute myeloid leukemia. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35526025 | PubMed |
| 33407700 | Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/33407700 | PubMed |
| 32911532 | BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. | Blood | 2021 | https://conductscience.org/library/papers/32911532 | PubMed |
| 32635428 | Intercellular Mitochondrial Transfer in the Tumor Microenvironment. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32635428 | PubMed |
| 31780390 | Current treatment preferences in acute myeloid leukemia: a survey in Brazil. | Hematol Transfus Cell Ther | 2020 | https://conductscience.org/library/papers/31780390 | PubMed |
| 30968179 | Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. | Cancer Chemother Pharmacol | 2019 | https://conductscience.org/library/papers/30968179 | PubMed |
| 29683259 | Genital ulcers as diagnostic clue for acute myeloid leukaemia. | Int Wound J | 2018 | https://conductscience.org/library/papers/29683259 | PubMed |
| 29043232 | Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. | Blood Res | 2017 | https://conductscience.org/library/papers/29043232 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23398482
GET https://conductscience.org/api/papers/v1/23398482/cited_by?page=2